References:

  1. Seer Stat Fact Sheets: Breast Cancer. http://seer.cancer.gov/statfacts/html/breast.html
  2. Breastcancer.org American Cancer Society. Breast Cancer detailed guide. http://www.cancer.org/cancer/breastcancer/detailedguide/index
  3. Worldwide Breast Cancer. http://www.worldwidebreastcancer.com/what-does-breast-cancer-look-like/
  4. American Cancer Society. Breast Cancer in Men detailed guide. http://www.cancer.org/cancer/breastcancerinmen/detailedguide/breast-cancer-in-men-key-statistics
  5. Ruddy KJ, et al. Breast cancer presentation and diagnostic delays in young women. Cancer 2014; 120(1):20-5 (http://www.ncbi.nlm.nih.gov/pubmed/24347383).
  6. Metcalfe K, et al. The Risk of Ovarian Cancer after Breast Cancer in BRCA1 and BRCA2 Carriers. Gynecologic Oncology 2005;96:222-226
  7. U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Recommendation statement. Ann Intern Med 2014; 160(4):271-81.
  8. American Society of Clinical Oncology: Breast Cancer http://www.cancer.net/cancer-types/breast-cancer
  9. Ford D, et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994. 343;692-695.
  10. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Screening and Diagnosis. v1.2015
  11. American Cancer Society. http://www.cancer.org/cancer/breastcancer/moreinformation/breastcancerearlydetection/breast-cancer-early-detection-prevention
  12. American College of Radiology. http://www.mammographysaveslives.org/Facts
  13. Breastcancer.org. http://www.breastcancer.org/risk/factors
  14. Breast Cancer.org. http://www.breastcancer.org/symptoms/understand_bc/statistics)
  15. National Cancer Institute. http://www.cancer.gov/types/breast/adjuvant-fact-sheet
  16. American Cancer Society. http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-treating-targeted-therapy
  17. Genentec. http://www.gene.com/media/product-information/herceptin-development-timeline
  18. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer v3.2015
  19. Hartmann LC, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. NEJM. 1999, 340:77-84.
  20. Gonzalez-Angulo AM, et al. Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer. AACR 2011;17(5):1082-9.
  21. Hartman AR, et al. Prevalence of BRCA Mutations in an Unselected Population of Triple Negative Breast Cancer. Cancer 2011;epub online.
  22. American Cancer Society. http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-classifying
  23. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High Risk Assessment: Breast and Ovarian. V2.2015
  24. Triple Negative Breast Cancer Foundation. http://www.tnbcfoundation.org/tnbcnews-platinum/
  25. U.S. Food and Drug Administration. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm407297